Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 5, 2009, Pages 520-526

  Komoroski, B ^a   Vachharajani, N ^a   Boulton, D ^a   Kornhauser, D ^a   Geraldes, M ^a   Li, L ^a   Pfister, M ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPAGLIFLOZIN; GLUCOSE; PLACEBO; PROTEIN INHIBITOR; SODIUM GLUCOSE COTRANSPORTER 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; ERYTHEMA; FACE EDEMA; FATIGUE; FEMALE; FLANK PAIN; GLUCOSE ABSORPTION; GLUCOSURIA; GLYCEMIC INDEX; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERHIDROSIS; HYPOGLYCEMIA; HYPOTENSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; PALLOR; PRIORITY JOURNAL; PRURITIC RASH; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; STRESS; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; GLUCOSIDES; GLYCOSURIA; HALF-LIFE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; SODIUM-GLUCOSE TRANSPORTER 2; TIME FACTORS;

EID: 67349180574     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.251     Document Type: Article

References (28)

1. van den Arend, I.J., Stolk, R.P., Krans, H.M., Grobbee, D.E. & Schrijvers, A.J. Management of type 2 diabetes: a challenge for patient and physician. Patient Educ. Couns. 40, 187-194 (2000).
2. Wagman, A.S. & Nuss, J.M. Current therapies and emerging targets for the treatment of diabetes. Curr. Pharm. Des. 7, 417-450 (2001).
3. Diabetes Atlas 3rd edn. (International Diabetes Federation, Brussels, Belgium, 2006).
4. Emanuele, N. et al. Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes ( VA CSDM). A feasibility study. Diabetes Care 19, 1375-1381 (1996).
5. Klein, R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 18, 258-268 (1995).
6. Porte, D. Jr. & Schwartz, M.W. Diabetes complications: why is glucose potentially toxic? Science 272, 699-700 (1996).
7. Bell, D.S. Type 2 diabetes mellitus: what is the optimal treatment regimen? Am. J. Med. 116 (suppl. 5A), 23S-29S (2004).
8. Jani, R., Triplitt, C., Reasner, C. & Defronzo, R.A. First approved inhaled insulin therapy for diabetes mellitus. Expert Opin. Drug. Deliv. 4, 63-76 (2007).
9. Turner, R.C., Cull, C.A., Frighi, V. & Holman, R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281, 2005-2012 (1999).
10. Wright, E.M., Hirayama, B.A. & Loo, D.F. Active sugar transport in health and disease. J. Intern. Med. 261, 32-43 (2007).
11. Handlon, A.L. Sodium glucose co-transporter 2 (SGLT2) inhibitors as potential antidiabetic agents. Expert Opin. Ther. Patents 15, 1431-1540 (2005).
12. Brown, G.K. Glucose transporters: structure, function and consequences of defciency. J. Inherit. Metab. Dis. 23, 237-246 (2000).
13. Rahmoune, H., Thompson, P.W., Ward, J.M., Smith, C.D., Hong, G. & Brown, J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54, 3427-3234 (2005).
14. Calado, J. et al. Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting. Kidney Int. 69, 852-855 (2006).
15. Francis, J., Zhang, J., Farhi, A., Carey, H. & Geller, D.S. A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria. Nephrol. Dial. Transplant. 19, 2893-2895 (2004).
16. Adachi, T. et al. T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats. Metabolism 49, 990-995 (2000).
17. Castaneda, F., Burse, A., Boland, W. & Kinne, R.K. Thioglycosides as inhibitors of hSGLT1 and hSGLT2: potential therapeutic agents for the control of hyperglycemia in diabetes. Int. J. Med. Sci. 4, 131-139 (2007).
18. Isaji, M. Sodium-glucose cotransporter inhibitors for diabetes. Curr. Opin. Investig. Drugs 8, 285-292 (2007).
19. Katsuno, K. et al. Serglifozin, a novel selective inhibitor of low-afnity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J. Pharmacol. Exp. Ther. 320, 323-330 (2007).
20. Han, S. et al. Dapaglifozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57, 1723-1729 (2008).
21. Meng, W. et al. Discovery of dapaglifozin: a potent, selective renal sodiumdependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 51, 1145-1149 (2008).
22. Calado, J., Soto, K., Clemente, C., Correia, P. & Ruef, J. Novel compound heterozygous mutations in SLC5A2 are responsible for autosomal recessive renal glucosuria. Hum. Genet. 114, 314-316 (2004).
23. Santer, R. et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J. Am. Soc. Nephrol. 14, 2873-2882 (2003).
24. Oemar, B.S., Byrd, D.J. & Brodehl, J. Complete absence of tubular glucose reabsorption: a new type of renal glucosuria (type 0). Clin. Nephrol. 27, 156-160 (1987).
25. Boyle, P.J. & Zrebiec, J. Physiological and behavioral aspects of glycemic control and hypoglycemia in diabetes. South. Med. J. 100, 175-182 (2007).
26. Rossetti, L., Smith, D., Shulman, G.I., Papachristou, D. & DeFronzo, R.A. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J. Clin. Invest. 79, 1510-1515 (1987).
27. Oku, A. et al. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 48, 1794-1800 (1999).
28. Komoroski, B., Vachharajani, N., Feng, Y., Li, L., Kornhauser, D. & Pfster, M. Dapaglifozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin. Pharmacol. Ther. XX, this issue (2009).